Engflag

Tigacil

Quick links to important sections

Tigacil

Selected form

Tigacil_ES

Treatment option: Bacterial Pneumonia, Bacteremia, Ventilator, Influenza, Infection, Complicated Skin And Skin Structure Infection, Pneumonia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tigacil

Quick Facts

Property Description
Active ingredient Tigecycline
Form Lyophilized powder for infusion (Injection)
Pharmacological class Glycylcycline (Antibiotic)
Typical use Treating serious, multi-drug resistant bacterial infections
Origin Synthetic (Man-made)
Prescription Status Prescription Only (Rx)

What Type of Antibiotic is Tigacil?

Tigacil, containing the active ingredient Tigecycline, is the first member of a unique, synthetic class of antibiotics called Glycylcyclines. It is structurally related to the older Tetracycline family, but its chemical modifications were designed to overcome bacterial resistance mechanisms, such as efflux pumps, which render many traditional antibiotics ineffective. This development resulted in the drug being clinically recognized for its ability to treat serious infections caused by multi-drug resistant organisms. Tigecycline's use is reserved for adult patients (18 and older) and must be administered under medical supervision, reflecting its powerful nature and role as a crucial option when common treatments are inadequate.

Composition and Origin: The Specialized IV Powder

Tigacil is supplied as a sterile, freeze-dried powder for solution for infusion. Its formulation contains a single active ingredient, Tigecycline. The medication is only administered via the intravenous (IV) route—it must be mixed with a liquid and slowly delivered directly into a patient's vein over 30 to 60 minutes. The mandatory IV-only route is due to the drug being poorly absorbed when taken orally, confirming the necessity of parenteral delivery to ensure the drug reaches therapeutic concentrations in the bloodstream.

How Does the Glycylcycline Class Fight Infection?

The mechanism by which Tigecycline acts is bacteriostatic, meaning it works by stopping bacteria from growing and reproducing, rather than directly killing them. Pharmacological studies confirm that Tigecycline achieves this by binding tightly to the bacteria's 30S ribosomal subunit, which is essential for making proteins. By interrupting protein synthesis, the drug effectively halts the multiplication of bacteria. This highly specific action provides a strategic advantage, giving the patient's immune system the time required to clear the established infection, particularly those caused by highly resistant bacteria.

Regulatory References

  1. MedlinePlus: Tigecycline Route

What side effects are possible with Tigacil?

The possible side effects and safety characteristics of Tigacil (Tigecycline) are established and classified in official regulatory documents based on clinical trial data.

Adverse Reaction Classifications

Side effects are categorized by the body systems affected (System-Organ Classes) and by their observed frequency. Gastrointestinal disorders are the most frequently reported adverse reactions.

Frequency Category Representative Adverse Reactions
Very Common Nausea, Vomiting (often most frequent at the beginning of treatment)
Common Diarrhea, Abdominal pain, Headache, Dizziness, Injection site reactions, Elevated liver transaminases (ALT/AST)
Uncommon Acute pancreatitis, Sepsis, Jaundice, Clostridium difficile-associated diarrhea (CDAD)
Rare Anaphylactic reaction (severe hypersensitivity)

Serious Safety Information

Official labeling highlights specific serious risks that inform the overall safety profile:

  • Increased All-Cause Mortality: Pooled analyses of clinical trials have observed an increase in all-cause mortality in Tigecycline-treated patients compared to control groups. The cause of this signal remains officially undetermined.
  • Acute Pancreatitis: Cases of acute pancreatitis, including fatalities, have been reported; this is formally classified as an Uncommon but serious reaction.
  • Other Serious Events: The regulatory profile also includes reports of Liver Failure and Anaphylaxis/Anaphylactoid reactions.

Population-Specific Safety Notes

The label defines specific constraints for certain patient groups:

  • Severe Hepatic Impairment (Child-Pugh C): A reduced maintenance dosage is required due to reduced drug clearance in this population.
  • Pediatric Use: Use in patients under 8 years of age is not recommended due to the potential for permanent tooth discoloration and inhibition of bone growth, based on general effects observed with the tetracycline drug class. The safety and efficacy for pediatric patients over 8 years remain limited.
  • Restrictions: The drug is specifically not indicated for use in certain conditions, such as diabetic foot infection or hospital-acquired pneumonia, reflecting safety and outcome concerns noted in clinical trial data.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for a high-dose exposure to Tigecycline is established by documented clinical observations and severe systemic risks. In studies involving healthy volunteers, the administration of a single 300 mg dose was associated with an increased incidence of nausea and vomiting.

Required Emergency Actions

The drug's overall safety profile highlights the potential for life-threatening outcomes that mandate urgent medical attention. These include the risk of acute pancreatitis (with fatal cases reported), hepatic failure, and serious anaphylactic reactions. Furthermore, the FDA has identified an increased risk of all-cause mortality in meta-analyses of clinical trials.

Immediate medical attention must be sought if a suspected overdose occurs or if any severe symptoms are present. It is also advised to contact a poison control centre for specific management guidance.

Management and Monitoring

Classification Regulatory Status
Specific Antidote None available; management is symptomatic and supportive.
Drug Removal Hemodialysis is not effective at removing the drug in significant quantities.
Monitoring Required monitoring of liver function tests, coagulation parameters, and amylase/lipase levels.

Patients with severe hepatic impairment (Child-Pugh C) are noted to be at higher risk for toxicity and require special consideration and careful observation.

Therapeutic Uses of Tigacil

Quick Facts: Tigacil Uses

  • Complicated Skin and Skin Structure Infections (cSSSI): Used to address severe skin infections involving deeper soft tissues.
  • Complicated Intra-abdominal Infections (cIAI): Used to support the management of complex infections within the abdominal cavity.
  • Community-Acquired Bacterial Pneumonia (CAP): Used to manage lung infections acquired outside of a hospital setting.

Main Uses and Therapeutic Domains

Tigacil is a medication utilized in adults to support the treatment of specific, serious bacterial infections. Its use is typically reserved for situations where alternative treatments may not be suitable. This medication is used for three main conditions:

  1. Complicated Skin and Skin Structure Infections (cSSSI): This includes infections that involve the subcutaneous tissues, fascia, or muscle, which may respond to this medication as part of the total care plan.
  2. Complicated Intra-abdominal Infections (cIAI): These are complex infections of the organs inside the abdomen, where Tigacil is used to address the susceptible bacterial organisms involved.
  3. Community-Acquired Bacterial Pneumonia (CAP): This refers to lung infections managed in an inpatient setting, which may show improvement with this treatment.

Eligibility and Restrictions for Use

Who Can and Cannot Use Tigacil?

Eligibility to use Tigacil (Tigecycline) is strictly defined by regulatory documents, focusing on age, allergic history, and specific medical conditions.

Eligibility and Exclusion Rules

Category Official Regulatory Status
Approved Age Group Patients 18 years of age and older only.
Absolute Contraindication Patients with a known hypersensitivity to Tigecycline or to any antibacterial drug of the tetracycline class.
Pediatric Restriction Use is not recommended in patients under 18. It is contraindicated in children 8 years and younger due to the risk of permanent tooth discoloration and bone growth inhibition.
Infection Exclusion Not indicated for treating hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), or diabetic foot infections.
Pregnancy/Lactation May cause fetal harm (due to bone and tooth effects). Lactating women must pump and discard breast milk during treatment and for 9 days after the last dose.
Hepatic Impairment Severe hepatic impairment (Child-Pugh C) requires a conditional use status with a reduced dose. No adjustment is needed for renal impairment.

Regulatory Eligibility Summary

Official labeling establishes the medicine as suitable only for adults (18+) who do not have a contraindicating allergy to the tetracycline drug class. The regulatory profile restricts its use by excluding specific, severe infection types, such as HAP and VAP. Use in pediatric patients and pregnant women is strongly cautioned against or prohibited due to its documented effect on developing bone and teeth.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tigacil (tigecycline) may interact with specific classes of medicinal products, necessitating close monitoring. These interactions are primarily defined by effects on drug concentrations and blood coagulation parameters.

Clinically Significant Interactions

Interacting Product Category Specific Medicines Interaction Summary
Anticoagulants Warfarin Concomitant use may alter warfarin clearance, leading to increased exposure. Coagulation parameters, such as prothrombin time, must be closely monitored due to the potential for increased bleeding risk.
Calcineurin Inhibitors Tacrolimus, Cyclosporine Tigacil may cause an increase in the serum trough concentrations of these immunosuppressants. To prevent drug toxicity, the serum concentrations of the calcineurin inhibitor must be monitored during Tigacil treatment.
Oral Contraceptives Combined Hormonal Contraceptives As with other antibacterial drugs, the concurrent use of Tigacil may render oral contraceptives less effective, potentially resulting in reduced protection.

Other Relevant Information

Tigacil is not extensively metabolized by cytochrome P450 enzymes and is therefore not expected to alter the metabolism of medicines processed by these enzyme systems. Additionally, the product must not be mixed with other medicinal products except those specified for preparation and dilution, as a procedural constraint.

Mechanism of Action

Tigacil's mechanism is driven by its high-affinity, reversible binding to the bacteria's 30S ribosomal subunit. This interaction acts as a physical block at the Aminoacyl (A) site, which immediately halts the process of protein synthesis and the elongation of polypeptide chains. The resulting physiological effect on the bacteria is bacteriostasis, meaning the drug suppresses the growth and multiplication of the bacterial population. The resulting bacteriostasis facilitates the host's normal immune response. The active ingredient, Tigecycline, possesses a unique chemical structure that creates a strong and stable molecular lock on the ribosome. This enhanced affinity is a functional feature that allows the drug to overcome bacterial defense systems, particularly the drug-exporting efflux pumps and ribosomal protection proteins systems associated with reduced drug efficacy, ensuring sustained inhibitory function. The effectiveness of this ribosomal inhibition is constrained in biological scenarios where bacteria possess efficient, intrinsic RND-type efflux pumps or low outer membrane permeability, which results in the drug's activity being significantly reduced or absent in those specific bacterial populations.

Dosage and Administration Information

How to Use Tigacil: Administration Guidelines

Tigacil, which contains the active ingredient Tigecycline, is supplied as a lyophilized powder for solution for infusion and is administered exclusively via the intravenous (IV) route. The medicine requires reconstitution and subsequent dilution before delivery into a vein.

Standard Dosing and Schedule

The recommended adult dosing regimen begins with a single initial dose of 100 mg, followed by a consistent maintenance dose of 50 mg every 12 hours. Each intravenous infusion must be administered slowly over a duration of approximately 30 to 60 minutes.

The duration of treatment is guided by the infection type and clinical response, generally ranging from 5 to 14 days for complicated skin and intra-abdominal infections, and 7 to 14 days for community-acquired bacterial pneumonia (CAP). If a dose is missed, it should be given as soon as possible to maintain the 12-hour schedule.

Population-Specific Adjustments

Specific modifications are defined based on liver function:

Patient Population Dosing Rule
Severe Hepatic Impairment (Child-Pugh C) Maintenance dose must be reduced to 25 mg every 12 hours (following the 100 mg initial dose).
Renal Impairment (All degrees) No dosage adjustment is necessary.
Pediatric Use (8 to 17 years) Use is specialized; dosing is weight-based for children 8 to <12 years, up to a maximum of 50 mg every 12 hours.

Recent Clinical Evidence

Research evidence / Overview of Studies for Tigacil

Evidence for use in Complicated Skin and Skin Structure Infections (cSSSI)

This section summarizes the structure of the clinical evidence for complicated skin and skin structure infections (cSSSI), focusing on the design of the Randomized Controlled Trials (RCTs) used in the research that was submitted to regulatory authorities, and the types of endpoints (like clinical response) that researchers measured in adult patients.

The initial research was conducted through large, short-term RCTs. These studies were designed to compare Tigacil against established combination antibiotic treatments in adult patients (18 and older) hospitalized with severe cSSSI. Researchers primarily measured the Clinical Response at a defined follow-up visit, known as the Test-of-Cure (TOC) visit. Findings describe patterns observed in the studies related to the measured clinical response at the TOC visit, but results apply only to the populations studied.

Evidence for use in Complicated Intra-abdominal Infections (cIAI)

The primary evidence for cIAI was obtained from comparative Randomized Controlled Trials (RCTs). These trials studied Tigacil in hospitalized adult patients with complex infections inside the abdominal cavity. Research examined the measured Clinical Response and Microbiologic Eradication rates at the TOC follow-up visit. The original trial program included only a small number of critically ill patients, meaning that results apply only to the populations studied.

Limitations, Uncertainties, and Future Research Gaps

A key concern observed in pooled data from the clinical development program is a numerical imbalance in all-cause mortality in the drug group compared to control groups. This pattern was observed in some studies and has been noted by regulatory bodies; the underlying reasons are not fully established. Furthermore, evidence is limited for its use in specific severe populations, such as critically ill patients, and it is not studied or indicated for conditions like Hospital-Acquired Pneumonia (HAP) or Ventilator-Associated Pneumonia (VAP).

Frequently Asked Questions (FAQ)

Common questions about Tigacil (FAQ)

Q: What is Tigacil used for?

A: Tigacil (tigecycline) is an antibiotic substance. It is typically administered to patients to address complicated skin and soft tissue infections and complicated intra-abdominal infections caused by certain bacteria. The decision to use this specific medication is often reserved for situations where other treatment options may not be suitable, in alignment with current medical guidelines.

Q: How does the antibiotic substance in Tigacil work?

A: The active substance in Tigacil, tigecycline, is designed to interfere with the bacteria's process of making proteins. This mechanism is believed to inhibit the growth and multiplication of susceptible bacteria. This action is the basis for its intended therapeutic effect against certain infections.

Q: What kind of research supports the use of Tigacil?

A: Clinical trials have explored the use of Tigacil in treating complicated skin and soft tissue infections and complicated intra-abdominal infections. Data from these studies typically report the clinical response rates observed in the patient groups receiving Tigacil. The findings contribute to the understanding of its profile when used for these specific indications.

Q: Can Tigacil be used outside of a hospital setting?

A: Tigacil is generally intended for use within a hospital or clinical environment, where patients can receive the medication by intravenous infusion and be appropriately monitored by healthcare professionals.

Q: Has research indicated any potential risks or side effects?

A: Like all medications, the use of Tigacil has been associated with various reported effects in clinical studies. Commonly reported findings include nausea and vomiting. Research has also noted that, when compared to other antibiotics in pooled analyses of certain trials, there was a consistent observation of a small, elevated rate of mortality among patients receiving tigecycline. Healthcare providers weigh these reported findings when determining the appropriate course of treatment. Any questions about individual risks should be directed to a treating physician.

Q: Does the research prove that Tigacil is superior to other antibiotics?

A: Available clinical trial data compare the observed outcomes of Tigacil against other antibiotics in controlled settings. The evidence supports its use for specific complicated infections when certain other options are unavailable or unsuitable. No definitive claim of overall superiority over all other antibiotics is established, and treatment choice depends on the specific patient's condition and the type of infection.

How should Tigacil be stored and disposed of?

Storage Conditions

Tigacil (tigecycline) powder for solution for infusion must be stored and handled according to specific regulatory requirements to maintain its integrity.

Product Form Required Storage Temperature
Unopened Powder 20 to 25 C (68 to 77 F), with permitted excursions to 15 to 30 C.
Reconstituted/Diluted Solution 24 hours maximum at room temperature (up to 25 C), or 48 hours maximum under refrigeration (2 to 8 C) when diluted with approved solutions.

Handling and Disposal

The solution must be visually inspected and discarded if it is not yellow to orange or if it contains particulates or dark discoloration. For child safety, the product must be stored out of the reach and sight of children. All unused product and waste material must be disposed of according to local requirements and should not be discarded via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBangladesh

flagRussia

Equivalent of Tigacil found in:

A-Z Index: